Chris Labaki
Overview
Explore the profile of Chris Labaki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
477
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jammihal T, Saliby R, Labaki C, Soulati H, Gallegos J, Peris A, et al.
Nat Cancer
. 2025 Jan;
6(2):372-384.
PMID: 39789182
Immune checkpoint inhibitors can lead to 'exceptional', durable responses in a subset of persons. However, the molecular basis of exceptional response (ER) to immunotherapy in metastatic clear cell renal cell...
2.
Camp S, He M, Cuoco M, Saad E, Pimenta E, Meli K, et al.
bioRxiv
. 2024 Nov;
PMID: 39605676
Renal cell carcinoma (RCC) is characterized by recurrent somatic mutations in epigenetic regulators, which stratify patients into clinically significant subgroups with distinct prognoses and treatment responses. However, the cell type-specific...
3.
Labaki C, Uche-Anya E, Berzin T
Gastroenterol Clin North Am
. 2024 Nov;
53(4):773-786.
PMID: 39489586
Recent advancements in artificial intelligence (AI) have significantly impacted the field of gastrointestinal (GI) endoscopy, with applications spanning a wide range of clinical indications. The central goals for AI in...
4.
Greco F, Labaki C, Rassy E
Lancet Oncol
. 2024 Jul;
25(8):955-956.
PMID: 39068942
No abstract available.
5.
El Zarif T, Semaan K, Eid M, Seo J, Garinet S, Davidsohn M, et al.
Cell Rep
. 2024 Jun;
43(6):114350.
PMID: 38870013
Renal cell carcinoma with sarcomatoid differentiation (sRCC) is associated with poor survival and a heightened response to immune checkpoint inhibitors (ICIs). Two major barriers to improving outcomes for sRCC are...
6.
Saad E, Gebrael G, Semaan K, Eid M, Saliby R, Labaki C, et al.
Oncologist
. 2024 Apr;
29(8):699-706.
PMID: 38630540
Background: Current tobacco smoking is independently associated with decreased overall survival (OS) among patients with metastatic renal cell carcinoma (mRCC) treated with targeted monotherapy (VEGF-TKI). Herein, we assess the influence...
7.
Saliby R, Labaki C, Jammihal T, Xie W, Sun M, Shah V, et al.
Cancer Cell
. 2024 Apr;
42(5):732-735.
PMID: 38579722
Saliby et al. show that a machine learning approach can accurately classify clear cell renal cell carcinoma (RCC) into distinct molecular subtypes using transcriptomic data. When applied to tumors biospecimens...
8.
Han S, Camp S, Chu H, Collins R, Gillani R, Park J, et al.
Eur Urol Open Sci
. 2024 Mar;
62:107-122.
PMID: 38496821
Background And Objective: Previous germline studies on renal cell carcinoma (RCC) have usually pooled clear and non-clear cell RCCs and have not adequately accounted for population stratification, which might have...
9.
Castellano C, Sun T, Ravindranathan D, Hwang C, Balanchivadze N, Singh S, et al.
Cancer
. 2024 Feb;
130(12):2191-2204.
PMID: 38376917
Background: COVID-19 can have a particularly detrimental effect on patients with cancer, but no studies to date have examined if the presence, or site, of metastatic cancer is related to...
10.
Guram K, Huang J, Mouchati C, Abdallah N, Jani C, Navani V, et al.
Cancer
. 2024 Feb;
130(11):2003-2013.
PMID: 38297953
Background: Existing data on the impact of Hispanic ethnicity on outcomes for patients with renal cell carcinoma (RCC) is mixed. The authors investigated outcomes of Hispanic and non-Hispanic White (NHW)...